India to United States: Celecoxib Export Trade Route

The India to United States Celecoxib corridor is one of India's established pharmaceutical export routes, with 836 shipments documented worth a combined $58.4M USD. The route is dominated by UMEDICA LABORATORIES PRIVATE LIMITED, which alone accounts for roughly 41% of all export value, reflecting the consolidated nature of India's celecoxib manufacturing sector.

Across 17 active suppliers, the average shipment value stands at $69.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with celecoxib's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 14.8%, placing it at rank #14 among India's top celecoxib export destinations globally.

On the import side, key buyers of Indian celecoxib in United States include LIFESCIENCE LOGISTICS, MACLEODS PHARMA USA ,INC, J. KNIPPER & COMPANY and 41 others. LIFESCIENCE LOGISTICS is the single largest importer with 40 shipments valued at $23.6M USD.

India's celecoxib exports to United States are driven primarily by a handful of large-scale manufacturers. UMEDICA LABORATORIES PRIVATE LIMITED with 45 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 17 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — UMEDICA LABORATORIES PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, ALEMBIC PHARMACEUTICALS LIMITED — together account for 80% of total trade value on this route. The average shipment value of $69.9K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as celecoxib capsules 100 mg bno:bcb92316amd.10/23 ed. 09/26 ps: 1x500s and celecoxib capsules 100 mg bno:bcb92315a/bcb92317a md.10/23 ed.09/28 ps: 1x100s, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, LIFESCIENCE LOGISTICS is the largest importer with 40 shipments worth $23.6M USD — representing 40% of all celecoxib imports from India on this route. A total of 44 buyers are active on this corridor.